Read the quarter in context.
A source-linked quarter view: reported numbers, management language, guidance, and the risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹8,382 Cr
verified against source
Revenue YoY
11%
reported change
EBITDA
₹1,792 Cr
latest reported figure
Source
screener in
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Aurobindo Pharma delivered a strong Q4 FY25 with revenue of INR 8,382 crore (+11% YoY) and EBITDA of INR 1,792 crore (21.4% margin), driven by volume growth in US and Europe, stable pricing, and easing raw material costs. Full-year revenue reached INR 31,724 crore (+9% YoY) with EBITDA margin expanding to 20.8%. US formulation grew 13% YoY to INR 4,072 crore, Europe grew 17% to INR 2,147 crore, and the injectable business rose 25% YoY. Management guided for high single-digit revenue growth in FY26 (excluding transient products) and aims to maintain current EBITDA margins, though tariff announcements in July 2025 add uncertainty. Key risks include the Pen-G plant fire disruption, potential US tariffs, and muted injectable growth in FY26 pending FDA clearance of Eugia-3.
Colored figures show movement against the previous available record.
Guidance to track
- Management expects revenue growth of 8-9% in FY26, excluding the contribution from transient products like Revlimid.
- The company internally aims to keep EBITDA margins at present levels (around 20.8%) for FY26.
- The China plant, commercialized in FY25, is expected to contribute revenues in FY26 and turn breakeven or slightly positive.
- The US-based OSD plant at Dayton is expected to commence commercial manufacturing in Q2 of FY26.
Risks flagged
- A fire incident at the Pen-G facility in Kakinada has halted production; resumption depends on regulatory approvals, impacting FY26 revenue and margin assumptions.
- Tariff announcements expected in July 2025 could impact US business; management declined to provide specific guidance until clarity emerges.
- Eugia-3 facility remains under FDA remediation; injectable growth is expected to be flat in FY26, with recovery only in FY27.
- Revenue from Revlimid will be significantly lower in FY26 as the product faces increased competition and limited remaining supply.
Key quotes
- We have achieved excellent overall performance across business during FY 2025. With focused approach and right strategies in place, we are confident to continue our growth trajectory.
- FY 2026 will be muted in terms of growth per se because obviously you said it right. Eugia-3 is yet to be cleared, and there's no superstar product which is going to come in FY 2026.
- We expect 2028 would be the inflection year for the biosimilar business. The business will stabilize with about seven products in the regulated markets, both in Europe and possibly a couple of products in the U.S. by 2028.
Research modules